Head-to-head · Value Score
CoreAge Rx vs Peter MD
Two GLP-1 deals, scored on the same six factors. CoreAge Rx lands a Value Score of 93, Peter MD a 74. Here's who gives you the honest lower price — and where each one bites back.
CoreAge Rx
#1 · Grade A+ · Best Value
Est. first month
$149/mo
Save ~89% vs brand-namePeter MD
#105 · Grade C+ · Watch List
Est. first month
$149/mo
Save ~89% vs brand-nameThe verdict
CoreAge Rx takes it on Value Score, 93 to 74 — an est. $149/mo first month, with no teaser step-up baked in. Peter MD isn't out of it: Shoppers who want to consolidate GLP-1 with other treatments — testosterone, NAD+, sermorelin, ED or hair loss — on a single account, and who will budget for tirzepatide's $249/mo rate from month two rather than anchoring on the $149 intro.
CoreAge Rx is also our overall #1 pick across the whole deals board — a flat, all-in price on both molecules in all 50 states. That's why it wins here on the score, not just this matchup.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | CoreAge Rx | Peter MD |
|---|---|---|
| Value Score | 93 (A+) | 74 (C+) |
| Est. first month | $149/mo | $149/mo |
| Save vs brand-name | ~89% | ~89% |
| Semaglutide | $149/mo | $149/mo first-time (Level 1), $139/mo returning (Level 2) — compounded w/ B12 |
| Tirzepatide | $349/mo | $149 first month, then $249/mo billed quarterly (60mg) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | All 50 states | Nationwide, but restrictions vary by treatment — AL/ID excluded across the board; tirzepatide also excluded in AR/CA/MI/NC/TX; B-12 also excluded in AR/CA/KY/LA/SC |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
CoreAge Rx
The honest lowest price: both molecules at one flat, all-in monthly rate that never steps up after month one.
Why it's a deal
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation — no lock-in
The fine print
- Not the rock-bottom sticker — a couple of teaser tiers advertise lower month-one rates
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Peter MD
A physician-prescribed telehealth account that puts GLP-1 (tirzepatide and compounded semaglutide+B12) alongside TRT, NAD+, sermorelin, ED and hair-loss treatment under one login — with a genuine month-two step-up on tirzepatide to plan around.
Why it's a deal
- Broad product line under one account — TRT, ED, weight loss, GLP-1, NAD+ and men's hair loss — useful if you want more than a single GLP-1 script
- Physician-prescribed and nationwide in structure, not a single-state clinic
- Semaglutide's returning-patient rate ($139/mo) is genuinely cheaper than its first-time rate, not a bait-and-switch in that direction
- Tirzepatide's $149 first month is a real, disclosed price, not a hidden fee
The fine print
- Tirzepatide's real ongoing rate is $249/mo billed quarterly, not the $149 headline — a step-up to budget for, not a flat price
- State restrictions vary by treatment and the full list isn't disclosed on the customer-facing marketing pages — confirm your state for the specific treatment you want before signing up
- Customer reviews are mixed
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores CoreAge Rx is ranked on the CoreAge Rx alternatives board, and the same list for the other side is on alternatives to Peter MD.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.